MX2009006252A - Sal de tanato de rasagilina. - Google Patents

Sal de tanato de rasagilina.

Info

Publication number
MX2009006252A
MX2009006252A MX2009006252A MX2009006252A MX2009006252A MX 2009006252 A MX2009006252 A MX 2009006252A MX 2009006252 A MX2009006252 A MX 2009006252A MX 2009006252 A MX2009006252 A MX 2009006252A MX 2009006252 A MX2009006252 A MX 2009006252A
Authority
MX
Mexico
Prior art keywords
rasagiline
tannate salt
tannate
salt
compositions
Prior art date
Application number
MX2009006252A
Other languages
English (en)
Inventor
Anton Frenkel
Tamas Koltai
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2009006252A publication Critical patent/MX2009006252A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención objeto proporciona tanato de rasagilina, composiciones y un proceso para la fabricación del mismo.
MX2009006252A 2006-12-14 2007-12-13 Sal de tanato de rasagilina. MX2009006252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87503806P 2006-12-14 2006-12-14
PCT/US2007/025516 WO2008076315A1 (en) 2006-12-14 2007-12-13 Tannate salt of rasagiline

Publications (1)

Publication Number Publication Date
MX2009006252A true MX2009006252A (es) 2009-10-13

Family

ID=39536617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006252A MX2009006252A (es) 2006-12-14 2007-12-13 Sal de tanato de rasagilina.

Country Status (23)

Country Link
US (1) US7547806B2 (es)
EP (1) EP2101570B1 (es)
JP (1) JP5356248B2 (es)
KR (1) KR101077835B1 (es)
CN (1) CN101600346B (es)
AU (1) AU2007334493B2 (es)
BR (1) BRPI0718339A2 (es)
CA (1) CA2672452C (es)
DK (1) DK2101570T3 (es)
EA (1) EA016843B1 (es)
ES (1) ES2420124T3 (es)
HR (1) HRP20130396T1 (es)
IL (1) IL198984A (es)
MX (1) MX2009006252A (es)
NO (1) NO20092609L (es)
NZ (1) NZ577623A (es)
PL (1) PL2101570T3 (es)
PT (1) PT2101570E (es)
RS (1) RS52784B (es)
SI (1) SI2101570T1 (es)
UA (1) UA97382C2 (es)
WO (1) WO2008076315A1 (es)
ZA (1) ZA200903904B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
HRP20130622T1 (en) * 2005-02-17 2013-08-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2901244A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) * 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
RS52183B (sr) 2006-12-14 2012-10-31 Teva Pharmaceutical Industries, Ltd. Kristalna čvrsta baza razagilina
BRPI0718339A2 (pt) 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032273A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
US20120269871A1 (en) 2009-12-30 2012-10-25 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited Rasagiline salts and processes for the preparation thereof
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
HK1200314A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceuticals Usa, Inc. R(+)-n-methyl-propargyl-aminoindan
EP2827848B1 (en) 2012-03-21 2016-04-27 Synthon BV Stabilized pharmaceutical compositions comprising rasagiline salts
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
CA2945681A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Sitagliptin tannate complex
CN107125438A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂鞣酸生物碱及其制备方法以及一种复合添加剂和一种饲料
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) * 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
WO2002005745A2 (en) * 2000-07-14 2002-01-24 Cadila Pharmaceuticals Limited The process of manufacturing pharmaceutical grade tannates
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
EP1628656B1 (en) * 2003-03-25 2008-10-15 Kiel Laboratories, Inc. Gabapentin tannate in liquid and/or semi-solid dosage forms
EP2181995A3 (en) * 2003-09-03 2010-06-16 Glaxo Group Limited Salts and crystalline form of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate
US20050053656A1 (en) * 2003-09-05 2005-03-10 Ping Jeffrey H. Compositions and methods for treating pain
US20050202050A1 (en) * 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
EP1778196A4 (en) 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
EP1827409B1 (en) 2004-11-24 2011-08-24 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
CA2901244A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2009521402A (ja) 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
BRPI0718339A2 (pt) 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff

Also Published As

Publication number Publication date
EP2101570B1 (en) 2013-02-13
CN101600346A (zh) 2009-12-09
NO20092609L (no) 2009-09-04
EA200970580A1 (ru) 2009-12-30
ES2420124T3 (es) 2013-08-22
KR101077835B1 (ko) 2011-10-28
DK2101570T3 (da) 2013-05-27
AU2007334493B2 (en) 2010-12-02
AU2007334493A1 (en) 2008-06-26
PL2101570T3 (pl) 2013-07-31
IL198984A (en) 2013-03-24
RS52784B (sr) 2013-10-31
JP5356248B2 (ja) 2013-12-04
PT2101570E (pt) 2013-05-17
US20080146676A1 (en) 2008-06-19
EA016843B1 (ru) 2012-07-30
CA2672452A1 (en) 2008-06-26
BRPI0718339A2 (pt) 2014-02-18
SI2101570T1 (sl) 2013-06-28
HK1129277A1 (en) 2009-11-27
NZ577623A (en) 2011-05-27
JP2010513280A (ja) 2010-04-30
HRP20130396T1 (en) 2013-06-30
EP2101570A1 (en) 2009-09-23
CN101600346B (zh) 2013-08-21
EP2101570A4 (en) 2011-04-06
WO2008076315A1 (en) 2008-06-26
ZA200903904B (en) 2010-08-25
CA2672452C (en) 2012-07-03
KR20090088433A (ko) 2009-08-19
UA97382C2 (ru) 2012-02-10
IL198984A0 (en) 2010-02-17
US7547806B2 (en) 2009-06-16

Similar Documents

Publication Publication Date Title
UA97382C2 (ru) Таннат разагилина
EG25147A (en) Process for the manufacture of 1,2-dichloroethane.
UA97502C2 (ru) Кристаллическая твердая основа разагилина
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
WO2007093627A3 (de) Biozide zusammensetzung
EG25812A (en) Process for the manufacture of 1,2-dichloroethane
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
MX284139B (es) Produccion de isoprenoides.
TW200745261A (en) Aqueous dispersions based on nitrocellulose-polyurethane particles
ZA200904333B (en) Process for the preparation of 6,6-Dimethyl-3-azabicyclo-[3.1.0]-hexane compounds utilizing bisulfite intermediate
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
MX2009005631A (es) Sulfuro de zinc transparente que tiene alta area superficial especifica.
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
MX2009009490A (es) Profarmacos novedosos.
WO2008015584A3 (en) Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
EG25292A (en) Process for the production of anilines.
TW200734339A (en) Forms of dolasetron mesylate and processes for their preparation
EP1996192A4 (en) PROCESS FOR PREPARING 3,4-SUBSTITUTED THIAZOLIDIN-2-ONES IN 3,4
TW200637832A (en) Process for preparing amorphous valsartan
IL192153A0 (en) Process for manufacturing entacapone
WO2008090465A3 (en) Process for synthesizing desvenlafaxine free base and salts or salvates thereof
WO2008029267A3 (de) Hydrochloride von 3-amino-2-hydroxycarbonsäureamiden
MX2009003196A (es) Proceso para la preparacion de y-butirolactonas.

Legal Events

Date Code Title Description
FG Grant or registration